Worldcrunch on MSN4d
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s
The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
France 2421h
The fight against Alzheimer’s disease: How effective and safe is lecanemab?
In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...
European regulators green light new Alzheimer's drug after first rejecting it
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Medpage Today on MSN8d
Alzheimer's Data Withdrawn
A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Medscape4d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
DPA International on MSN5d
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
ALZFORUM5d
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
Sveriges Radio1d
Swedish patients could face long wait for new early Alzheimer's drug
Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...